These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 6765542)
1. Comparison of the activity profiles of two fixed combinations of regular/NPH human insulin (recombinant DNA) of different compositions with a fixed regular/NPH porcine insulin combination (PPI) in insulin-dependent diabetic individuals. Sailer D; Ludwig T; Kolb S Diabetes Care; 1982; 5 Suppl 2():57-9. PubMed ID: 6765542 [TBL] [Abstract][Full Text] [Related]
2. A comparison of semisynthetic human NPH insulin and porcine NPH insulin in the treatment of insulin-dependent diabetes mellitus. Pedersen C; Høegholm A Diabet Med; 1987; 4(4):304-6. PubMed ID: 2956040 [TBL] [Abstract][Full Text] [Related]
3. Treatment with human insulin (recombinant DNA) in diabetic subjects pretreated with pork or beef insulin: first results of a multicenter study. Beyer J; Enzmann F; Lauerbach M; Althoff P; Bachmann W; Brandstetter K; Cordes U; Dannehl A; Düntsch G; Haas R Diabetes Care; 1982; 5 Suppl 2():140-8. PubMed ID: 6765526 [TBL] [Abstract][Full Text] [Related]
4. Comparative study of NPH human insulin (recombinant DNA) and NPH bovine insulin in diabetic subjects. Marre M; Tabbi-Anneni A; Tabbi-Anneni H; Assan R Diabetes Care; 1982; 5 Suppl 2():63-6. PubMed ID: 6765544 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of NPH human insulin (recombinant DNA) and pork insulin in diabetic subjects: preliminary report. Mirouze J; Monnier L; Richard JL; Gancel A; Soua KB Diabetes Care; 1982; 5 Suppl 2():60-2. PubMed ID: 6765543 [TBL] [Abstract][Full Text] [Related]
6. Crossover study with human insulin (recombinant DNA) in type I diabetic subjects. Landgraf R; Kammerer S; Bock T; Smolka B; Ladik T; Enzmann F; Landgraf-Leurs MM Diabetes Care; 1982; 5 Suppl 2():39-42. PubMed ID: 6765538 [TBL] [Abstract][Full Text] [Related]
7. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin. Olsson PO; Hans A; Henning VS Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of human insulin (recombinant DNA)--regular, NPH, and mixtures--obtained by the Gerritzen method in healthy volunteers. Weinges K; Ehrhardt M; Nell G; Enzmann F Diabetes Care; 1982; 5 Suppl 2():67-70. PubMed ID: 6765545 [TBL] [Abstract][Full Text] [Related]
9. Search for the most practical regular/NPH mixtures for type I diabetic patients. Renner R; Vocke K; Hepp KD Diabetes Care; 1982; 5 Suppl 2():53-6. PubMed ID: 6765541 [TBL] [Abstract][Full Text] [Related]
10. Human (recombinant DNA) and porcine NPH insulins are unequally effective in diabetic patients. A comparative study using continuous blood glucose monitoring. Richard JL; Rodier M; Cavalié G; Mirouze J; Monnier L Acta Diabetol Lat; 1984; 21(3):211-7. PubMed ID: 6393670 [TBL] [Abstract][Full Text] [Related]
11. Phase IV study comparing diurnal glycemic profile following the administration of 2 NPH plus regular human DNA recombinant insulin regimens in type 1 diabetes mellitus (T1DM) adult patients. Feleder EC; Yerino GA; Halabe EK; Tombazzi JL; Farias JM Arzneimittelforschung; 2012 Jun; 62(6):267-73. PubMed ID: 22438072 [TBL] [Abstract][Full Text] [Related]
12. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro. Ahmed AB; Home PD Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735 [TBL] [Abstract][Full Text] [Related]
13. Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Radziuk J; Pye S; Bradley B; Braaten J; Vignati L; Roach P; Bowsher R; DiMarchi R; Chance R Diabetologia; 1998 Jan; 41(1):116-20. PubMed ID: 9498640 [TBL] [Abstract][Full Text] [Related]
14. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. Ahmed AB; Mallias J; Home PD Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882 [TBL] [Abstract][Full Text] [Related]
16. Intermediate-acting insulin preparations: NPH and lente. Deckert T Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205 [TBL] [Abstract][Full Text] [Related]
17. The U.S. "new patient" and "transfer" studies. Galloway JA; Peck FB; Fineberg SE; Spradlin CT; Marsden JH; Allemenos D; Ingulli-Fattic J Diabetes Care; 1982; 5 Suppl 2():135-9. PubMed ID: 6765525 [TBL] [Abstract][Full Text] [Related]
18. Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique. Bottermann P; Gyaram H; Wahl K; Ermler R; Lebender A Diabetes Care; 1982; 5 Suppl 2():43-52. PubMed ID: 6765540 [TBL] [Abstract][Full Text] [Related]
19. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290 [TBL] [Abstract][Full Text] [Related]
20. Absorption of soluble and isophane semi-synthetic human and porcine insulin in insulin-dependent diabetic subjects. Pramming S; Lauritzen T; Thorsteinsson B; Johansen K; Binder C Acta Endocrinol (Copenh); 1984 Feb; 105(2):215-20. PubMed ID: 6364670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]